AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34170908 — intervention group
Group type: COMPARATOR
Intervention: IV placebo infusion
Number of subjects: 94
Study 34170908 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 94
Study 32216801 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadtree algorithm for population sampling frame
Number of subjects: 0
Study 32216801 — intervention group
Group type: COMPARATOR
Intervention: Uniform grid cells (UGC) approach (1×1 km and 3×3 km)
Number of subjects: 0
Study 35113238 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 132
Study 35113238 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 132
Study 32907500 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg donafenib twice daily for 24 weeks
Number of subjects: 35
Study 32907500 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg donafenib twice daily for 24 weeks
Number of subjects: 35
Study 32907500 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg donafenib
Number of subjects: 35
Study 32907500 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg donafenib
Number of subjects: 35
Study 35275569 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 pulses
Number of subjects: 13
Study 35275569 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 pulses
Number of subjects: 13
Study 35275569 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 pulses
Number of subjects: 13
Study 35275569 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 pulses
Number of subjects: 13
Study 32074977 — intervention group
Group type: EXPERIMENTAL
Intervention: Calanus oil supplementation plus exercise training
Number of subjects: 55
Study 32074977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil) plus exercise training
Number of subjects: 55
Study 32151176 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 120
Study 32151176 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 120
Study 32151176 — intervention group
Group type: COMPARATOR
Intervention: Vincristine
Number of subjects: 120
Study 35569283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (n = 151)
Number of subjects: 300
Study 35569283 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment (n = 149)
Number of subjects: 300
Study 35507037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral hamstring graft
Number of subjects: 100
Study 35507037 — intervention group
Group type: COMPARATOR
Intervention: Contralateral hamstring graft
Number of subjects: 100
Study 32161992 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 11
Study 32161992 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 11
Study 34480785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutritional education (at every outpatient visit)
Number of subjects: 96
Study 34480785 — intervention group
Group type: COMPARATOR
Intervention: Usual nutritional education (once a year)
Number of subjects: 96
Study 32167038 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of oral cholera vaccine (OCV)
Number of subjects: 211
Study 35862082 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin-ramipril combination treatment
Number of subjects: 30
Study 33914057 — intervention group
Group type: EXPERIMENTAL
Intervention: 59.4 Gy radiotherapy + concurrent and/or adjuvant temozolomide
Number of subjects: 751
Study 33914057 — intervention group
Group type: COMPARATOR
Intervention: 59.4 Gy radiotherapy
Number of subjects: 751
Study 34756518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (local anesthesia with 0.5% lidocaine + oral 200 mg Celecoxib + intravenous 40 mg parecoxib sodium + continuous intravenous 0.5 μg/kg/h dexmedetomidine)
Number of subjects: 128
Study 34756518 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive group (local anesthesia with 0.5% lidocaine + oral 200 mg Celecoxib + intravenous 40 mg parecoxib sodium)
Number of subjects: 128
Study 34756518 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (local anesthesia with 0.5% lidocaine)
Number of subjects: 128
Study 34756518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 128
Study 34756518 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive group
Number of subjects: 128
Study 34756518 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 128
Study 34756518 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 128
Study 33187485 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital education program delivering FP/RH information and economic empowerment training through storytelling.
Number of subjects: 6000
Study 36166756 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-distanced reflections
Number of subjects: 257
Study 36166756 — intervention group
Group type: COMPARATOR
Intervention: Self-immersed reflections
Number of subjects: 257
Study 34454710 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice alerts
Number of subjects: 28
Study 34454710 — intervention group
Group type: COMPARATOR
Intervention: Auditory icons
Number of subjects: 28
Study 32541348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pelvic elevation on the ipsilateral measurement side
Number of subjects: 12
Study 32541348 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior activity during lateral pelvic elevation
Number of subjects: 12
Study 33340750 — intervention group
Group type: EXPERIMENTAL
Intervention: Three virtual visits with a health educator in the 3rd trimester of pregnancy, at 3–4 weeks, and 3–4 months postpartum, along with continuous multimedia education through text messaging, print material, and videos.
Number of subjects: 0
Study 33340750 — intervention group
Group type: COMPARATOR
Intervention: Enhanced safety education control group.
Number of subjects: 0
Study 35909251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sponge-assisted surgery
Number of subjects: 150
Study 35909251 — intervention group
Group type: COMPARATOR
Intervention: Trendelenburg surgery
Number of subjects: 150
Study 33977284 — intervention group
Group type: EXPERIMENTAL
Intervention: RTB101 10 mg once daily
Number of subjects: 1676
Study 33977284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1676
Study 33977284 — intervention group
Group type: EXPERIMENTAL
Intervention: RTB101 10 mg in combination with everolimus 0.1 mg once daily
Number of subjects: 1676
Study 32468579 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 285
Study 32468579 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib exposure (Cavg,t)
Number of subjects: 285
Study 32468579 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of visceral disease
Number of subjects: 285
Study 32468579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline lactate dehydrogenase levels
Number of subjects: 285
Study 32468579 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free interval >12 months
Number of subjects: 285
Study 32468579 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended starting dose of talazoparib
Number of subjects: 285
Study 34662695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 146
Study 34662695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomatis sound therapy (TST)
Number of subjects: 146
Study 34662695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HBOT and TST
Number of subjects: 146
Study 34662695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 146
Study 33910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 60
Study 33910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices
Number of subjects: 60
Study 33910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 60
Study 33910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal surgery
Number of subjects: 60
Study 33910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft palate, tongue base or mandibular surgery
Number of subjects: 60
Study 33910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation
Number of subjects: 60
Study 35305913 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen 800 mg infusion
Number of subjects: 50
Study 35305913 — intervention group
Group type: COMPARATOR
Intervention: IV paracetamol 1 g infusion
Number of subjects: 50
Study 34428241 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered care model (FCCM)
Number of subjects: 379
Study 34428241 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 379
Study 37714931 — intervention group
Group type: EXPERIMENTAL
Intervention: Street football training (ST)
Number of subjects: 39
Study 37714931 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass football training (GR)
Number of subjects: 39
Study 37714931 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (CO)
Number of subjects: 39
Study 34185831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarette with 5.9% Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 191
Study 34185831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarette with 13.4% Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 191
Study 34185831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.02% THC)
Number of subjects: 191
Study 33736547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐sectorial lung team (CLT)
Number of subjects: 113
Study 33736547 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 113
Study 32195949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wrist‐ankle strap
Number of subjects: 78
Study 32195949 — intervention group
Group type: COMPARATOR
Intervention: Nonacupressure wrist‐ankle strap
Number of subjects: 78
Study 35613998 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT (8 Gy x 3 fractions) plus systemic therapy
Number of subjects: 384
Study 35613998 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 384
Study 32674691 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast (B) - Individualised breakfast (583±54 kcal; 8-9am) and lunch (874±80 kcal; 12-2pm)
Number of subjects: 11
Study 32674691 — intervention group
Group type: COMPARATOR
Intervention: No Breakfast (NB) - Fasting until 12pm and then consuming a standardised lunch (1457±134 kcal: 12-2pm)
Number of subjects: 11
Study 32064639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 8732
Study 32064639 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-school intervention only
Number of subjects: 8732
Study 32064639 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention only
Number of subjects: 8732
Study 32064639 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 8732
Study 35764191 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 256
Study 35764191 — intervention group
Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy (dCRT)
Number of subjects: 256
Study 34180122 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap transition (IDeg 1:1 at pump basal dose, pump continued for first 48 hours with gradual basal reduction)
Number of subjects: 30
Study 34180122 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (discontinued insulin pump and started IDeg in 1:1 dose)
Number of subjects: 30
Study 34180122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 32706198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation intervention using the BrainHQTM web-based platform (n = 23)
Number of subjects: 47
Study 32706198 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 47
Study 35696837 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-enhanced cognitive behavioral group therapy (IE-CBGT)
Number of subjects: 107
Study 35696837 — intervention group
Group type: COMPARATOR
Intervention: Verbal-based cognitive behavioral group therapy (VB-CBGT)
Number of subjects: 107
Study 33619188 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced usual care with in-person education about conservative kidney management and advance care planning (COPE)
Number of subjects: 0
Study 33619188 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 32134321 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy
Number of subjects: 0
Study 35837705 — intervention group
Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 0
Study 35837705 — intervention group
Group type: COMPARATOR
Intervention: pazopanib
Number of subjects: 0
Study 35837705 — intervention group
Group type: COMPARATOR
Intervention: methotrexate and vinblastine
Number of subjects: 0
Study 35837705 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate + vinca alkaloids
Number of subjects: 0
Study 35837705 — intervention group
Group type: EXPERIMENTAL
Intervention: cryotherapy
Number of subjects: 0
Study 35837705 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery
Number of subjects: 0
Study 35837705 — intervention group
Group type: EXPERIMENTAL
Intervention: radiotherapy
Number of subjects: 0
Study 32806958 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgusted face emoji
Number of subjects: 0
Study 32806958 — intervention group
Group type: EXPERIMENTAL
Intervention: Smiling face emoji
Number of subjects: 0
Study 32806958 — intervention group
Group type: COMPARATOR
Intervention: Text (no emoji)
Number of subjects: 0
Study 32806958 — intervention group
Group type: EXPERIMENTAL
Intervention: High involvement with inspection reports
Number of subjects: 0
Study 32806958 — intervention group
Group type: COMPARATOR
Intervention: Low involvement with inspection reports
Number of subjects: 0
Study 34429515 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus rhamnosus 271, 109 CFU)
Number of subjects: 36
Study 34429515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32081913 — intervention group
Group type: EXPERIMENTAL
Intervention: Living within 3 km of an incinerator
Number of subjects: 19519
Study 32081913 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 19519
Study 32081913 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in the city
Number of subjects: 19519
Study 35912473 — intervention group
Group type: EXPERIMENTAL
Intervention: Black VC using Standard American English (SAE)
Number of subjects: 282
Study 35912473 — intervention group
Group type: EXPERIMENTAL
Intervention: Black VC using African American English (AAE)
Number of subjects: 282
Study 33782699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit messages referring to coronavirus
Number of subjects: 1509
Study 33782699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit messages referring to risk of chest infection
Number of subjects: 1509
Study 33782699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit messages encouraging cessation for financial reasons
Number of subjects: 1509
Study 33782699 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1509
Study 35124183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 years
Number of subjects: 0
Study 35124183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 35124183 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (six cycles of platinum plus pemetrexed)
Number of subjects: 0
Study 35124183 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 34120925 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 26
Study 34120925 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 26
Study 36321618 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular block using peripheral nerve stimulation and ultrasonography
Number of subjects: 50
Study 33382352 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of omega-3 supplementation
Number of subjects: 0
Study 33382352 — intervention group
Group type: COMPARATOR
Intervention: 20 g of inulin (prebiotic) supplementation
Number of subjects: 0
Study 32486840 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized audit and feedback intervention (monthly feedback for 6 months)
Number of subjects: 316
Study 32486840 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-concordant antibiotics (amoxicillin and azithromycin)
Number of subjects: 316
Study 32486840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no personalized feedback)
Number of subjects: 316
Study 34038427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental Movement Skills (FMS)
Number of subjects: 117
Study 34038427 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Movement Patterns (QMP)
Number of subjects: 117
Study 34038427 — intervention group
Group type: COMPARATOR
Intervention: Poor FMS
Number of subjects: 117
Study 34038427 — intervention group
Group type: COMPARATOR
Intervention: Low QMP
Number of subjects: 117
Study 34038427 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys on object-control subtest and TGMD-2
Number of subjects: 117
Study 34038427 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls on FMS™
Number of subjects: 117
Study 34038427 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between MF, FMS, and QMP
Number of subjects: 117
Study 33734768 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength at Home Couples (SAH‐C) intervention
Number of subjects: 69
Study 33734768 — intervention group
Group type: COMPARATOR
Intervention: Supportive Prevention
Number of subjects: 69
Study 33080408 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoScan CNV Plus Assay (OS+)
Number of subjects: 46
Study 33080408 — intervention group
Group type: COMPARATOR
Intervention: Sanger sequencing
Number of subjects: 46
Study 33080408 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated OS+ algorithm
Number of subjects: 46
Study 32097058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound visual feedback (UVF)
Number of subjects: 38
Study 32097058 — intervention group
Group type: COMPARATOR
Intervention: Auditory perceptual training plus UVF
Number of subjects: 38
Study 32097058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 34045222 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of PGA therapy after cataract surgery (CPGA)
Number of subjects: 62
Study 34045222 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of PGA therapy
Number of subjects: 62
Study 33439974 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 544
Study 33439974 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 544
Study 33439974 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood interleukin-6 concentration at 1 hour after skin incision
Number of subjects: 544
Study 35418429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity brisk walking
Number of subjects: 0
Study 35418429 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-intensity brisk walking
Number of subjects: 0
Study 33745587 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation protocol in Leuven: commercial vitamins, trace elements, and electrolytes in separate infusions over 4 hours.
Number of subjects: 0
Study 33745587 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation protocol in Rotterdam: commercial vitamins and trace elements via 8-hour infusion and electrolytes continuously over 24 hours.
Number of subjects: 0
Study 33745587 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation protocol in Edmonton: commercial vitamins and institutionally prepared trace elements solutions in 1 hour and electrolytes on demand.
Number of subjects: 0
Study 32125256 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-coated balloon (DCB) angioplasty
Number of subjects: 171
Study 32125256 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty
Number of subjects: 171
Study 35777921 — intervention group
Group type: EXPERIMENTAL
Intervention: InSpace implant
Number of subjects: 184
Study 35777921 — intervention group
Group type: COMPARATOR
Intervention: Partial repair
Number of subjects: 184
Study 33636568 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen hoods/helmets
Number of subjects: 136
Study 33636568 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-flow oxygen delivery systems
Number of subjects: 136
Study 36290890 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise program
Number of subjects: 11
Study 36290890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 34571624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 93
Study 34571624 — intervention group
Group type: COMPARATOR
Intervention: Ologen implant
Number of subjects: 93
Study 34750705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray in sitting position (Group A)
Number of subjects: 0
Study 34750705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray in supine position (Group B)
Number of subjects: 0
Study 33814231 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose 20 μg recombinant hepatitis B vaccine
Number of subjects: 352
Study 33814231 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose 60 μg recombinant hepatitis B vaccine
Number of subjects: 352
Study 33814231 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak anti-HBs levels in 100–1000 mIU/mL or ≥ 1000 mIU/mL
Number of subjects: 352
Study 33814231 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic profile of anti-HBs levels
Number of subjects: 352
Study 33136781 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic i3.1
Number of subjects: 48